STOCK TITAN

Director at PROCEPT BioRobotics (PRCT) receives new RSU and option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PROCEPT BioRobotics director Taylor C. Harris received new equity awards as part of director compensation. He was granted 3,315 restricted stock units, each representing one share of Common Stock, and 5,853 stock options with an exercise price of $28.78 per share. Both the RSUs and options vest in full on the earlier of the one-year anniversary of the June 9, 2026 grant date or the next annual meeting, subject to continued service. After this award, Harris directly holds 102,491 shares of Common Stock.

Positive

  • None.

Negative

  • None.
Insider Harris Taylor C.
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 5,853 $0.00 --
Grant/Award Common Stock 3,315 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 5,853 shares (Direct, null); Common Stock — 102,491 shares (Direct, null)
Footnotes (1)
  1. These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
RSU grant 3,315 RSUs Restricted stock units granted June 9, 2026
Stock options granted 5,853 options Director stock option award on June 9, 2026
Option exercise price $28.78 per share Stock option strike price
Option expiration June 8, 2036 Option expiration date
Shares held after grant 102,491 shares Total Common Stock directly held after awards
Underlying shares for options 5,853 shares Common Stock underlying new stock options
restricted stock units (RSUs) financial
"These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock."
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise price of 28.7800 per share."
exercise price financial
"conversion_or_exercise_price: "28.7800" for the stock option grant."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The securities shall vest in full on the earlier to occur of the one-year anniversary of the grant date, or the date of the next annual meeting."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
annual meeting financial
"vest in full on the earlier of the one-year anniversary of the grant date, or the date of the next annual meeting."
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Harris Taylor C.

(Last)(First)(Middle)
C/O PROCEPT BIOROBOTICS CORPORATION
150 BAYTECH DRIVE

(Street)
SAN JOSE CALIFORNIA 95134

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PROCEPT BioRobotics Corp [ PRCT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/09/2026A(1)3,315A$0102,491D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$28.7806/09/2026A5,853 (2)06/08/2036Common Stock5,853$05,853D
Explanation of Responses:
1. These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
2. The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
Remarks:
/s/ Jonathan Stone, Attorney-in-Fact for Taylor C. Harris06/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did PROCEPT BioRobotics (PRCT) director Taylor C. Harris receive in this Form 4?

Taylor C. Harris received equity-based compensation consisting of 3,315 restricted stock units and 5,853 stock options. These awards increase his direct equity exposure to PRCT and are granted at no cash cost to him at the time of grant.

How many PROCEPT BioRobotics (PRCT) shares does Taylor C. Harris hold after this grant?

After the grant, Taylor C. Harris directly holds 102,491 shares of PROCEPT BioRobotics Common Stock. This total reflects the newly awarded 3,315 restricted stock units, which each represent one share when vested and settled, in addition to his prior holdings.

What are the key terms of the stock options granted to the PRCT director?

The director received 5,853 stock options with an exercise price of $28.78 per share. These options vest in full on the earlier of the one-year anniversary of the June 9, 2026 grant date or the next annual meeting, subject to continued service.

How do the restricted stock units (RSUs) for PROCEPT BioRobotics (PRCT) vest?

The 3,315 RSUs vest in full on the earlier of the one-year anniversary of the June 9, 2026 grant date or the next annual meeting. Vesting is contingent on the director’s continued service through the applicable vesting date.

Are these PRCT Form 4 transactions open-market purchases or sales?

These transactions are compensation-related grants, not open-market trades. The director acquired 3,315 RSUs and 5,853 stock options as awards, with no reported open-market buying or selling of PROCEPT BioRobotics Common Stock in this Form 4.